These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36710133)

  • 1. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting.
    Moore CM; King LE; Withington J; Amin MB; Andrews M; Briers E; Chen RC; Chinegwundoh FI; Cooperberg MR; Crowe J; Finelli A; Fitch MI; Frydenberg M; Giganti F; Haider MA; Freeman J; Gallo J; Gibbs S; Henry A; James N; Kinsella N; Lam TBL; Lichty M; Loeb S; Mahal BA; Mastris K; Mitra AV; Merriel SWD; van der Kwast T; Van Hemelrijck M; Palmer NR; Paterson CC; Roobol MJ; Segal P; Schraidt JA; Short CE; Siddiqui MM; Tempany CMC; Villers A; Wolinsky H; MacLennan S
    Eur Urol Oncol; 2023 Apr; 6(2):160-182. PubMed ID: 36710133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
    Moore CM; Giganti F; Albertsen P; Allen C; Bangma C; Briganti A; Carroll P; Haider M; Kasivisvanathan V; Kirkham A; Klotz L; Ouzzane A; Padhani AR; Panebianco V; Pinto P; Puech P; Rannikko A; Renard-Penna R; Touijer K; Turkbey B; van Poppel H; Valdagni R; Walz J; Schoots I
    Eur Urol; 2017 Apr; 71(4):648-655. PubMed ID: 27349615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
    Englman C; Maffei D; Allen C; Kirkham A; Albertsen P; Kasivisvanathan V; Baroni RH; Briganti A; De Visschere P; Dickinson L; Gómez Rivas J; Haider MA; Kesch C; Loeb S; Macura KJ; Margolis D; Mitra AM; Padhani AR; Panebianco V; Pinto PA; Ploussard G; Puech P; Purysko AS; Radtke JP; Rannikko A; Rastinehad A; Renard-Penna R; Sanguedolce F; Schimmöller L; Schoots IG; Shariat SF; Schieda N; Tempany CM; Turkbey B; Valerio M; Villers A; Walz J; Barrett T; Giganti F; Moore CM
    Eur Urol; 2024 Sep; 86(3):240-255. PubMed ID: 38556436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
    Willemse PM; Davis NF; Grivas N; Zattoni F; Lardas M; Briers E; Cumberbatch MG; De Santis M; Dell'Oglio P; Donaldson JF; Fossati N; Gandaglia G; Gillessen S; Grummet JP; Henry AM; Liew M; MacLennan S; Mason MD; Moris L; Plass K; O'Hanlon S; Omar MI; Oprea-Lager DE; Pang KH; Paterson CC; Ploussard G; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; Van den Broeck T; van der Kwast TH; van der Poel HG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TBL
    Eur Urol; 2022 Apr; 81(4):337-346. PubMed ID: 34980492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance.
    Merriel SWD; Moon D; Dundee P; Corcoran N; Carroll P; Partin A; Smith JA; Hamdy F; Moore C; Ost P; Costello T
    BMC Urol; 2021 Feb; 21(1):18. PubMed ID: 33541309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
    Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.
    Merriel SWD; Hetherington L; Seggie A; Castle JT; Cross W; Roobol MJ; Gnanapragasam V; Moore CM;
    BJU Int; 2019 Jul; 124(1):47-54. PubMed ID: 30742733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Active surveillance for low-risk prostate cancer].
    Herlemann A; Stief CG
    Urologe A; 2016 Feb; 55(2):269-81. PubMed ID: 26831055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.
    Donaldson IA; Alonzi R; Barratt D; Barret E; Berge V; Bott S; Bottomley D; Eggener S; Ehdaie B; Emberton M; Hindley R; Leslie T; Miners A; McCartan N; Moore CM; Pinto P; Polascik TJ; Simmons L; van der Meulen J; Villers A; Willis S; Ahmed HU
    Eur Urol; 2015 Apr; 67(4):771-7. PubMed ID: 25281389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
    Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
    Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
    Thomsen FB
    Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
    Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
    BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.
    Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath KV; Wessells H
    NIH Consens State Sci Statements; 2011 Dec 5-7; 28(1):1-27. PubMed ID: 23392076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.